Content of particular proteins indicating cellular injury due to apoptosis and necrosis has been investigated in ischemic/reperfused (IR) hearts and ischemic/reperfused hearts treated with CaMKII inhibitor and/or AT 1 receptor inhibitor. This data article provides information in support of the original research article "Oxidative activation of CaMKIIδ in acute myocardial ischemia/ reperfusion injury: a role of angiotensin AT 1 receptor-NOX2 signaling axis" [1].
Value of the data
The data can be useful for other researchers investigating signaling pathways associated with CaMKII and AT 1 receptor activation under setting of ischemia/reperfusion in the heart.
These data also provide significant contribution in understanding of pharmacological properties of AT 1 receptor inhibitors, drugs used in patients at high cardiovascular risk.
Data
In ischemic/reperfused (IR) group treated with CaMKII inhibitor, but not with AT 1 receptor inhibitor, Bcl-2/Bax ratio was significantly increased ( Fig. 1 ) and the expression of caspase-3 and 89 kDa apoptotic fragment of PARP1 was changed by neither CaMKII inhibition nor angiotensin AT 1 receptor inhibition (Fig. 2) . 40 kDa necrotic fragment of PARP1 was upregulated in the IR group and no intervention was able to normalize these levels (Fig. 3) . In the double-treated IR hearts, the levels of individual apoptotic and necrotic did not differ from those observed in either of mono-treated IR; however, the p 40PARP1/total PARP1 ratio was increased when compared to the IR group treated with CaMKII inhibitor alone.
Experimental design, materials and methods
Samples from the untreated and losartan and/or KN-93-treated hearts subjected to ischemia/ reperfusion injury were used to examine protein expression by immunoblotting.
Proteins were separated using the SDS-PAGE and transferred to PVDF membrane (EMD Millipore, USA). The primary antibodies used were Bcl-2 (Sigma-Aldrich, USA), Bax (Cell Signaling, USA), PARP1 (Cell Signaling, USA), Caspase-3 (csp-3) p17 (Santa Cruz Biotechnology, USA) and β-actin (Sigma-Aldrich, USA). A HRP-conjugated donkey anti-rabbit antibody (GE Healthcare Life Sciences, UK) was used as the secondary antibody. The signals of proteins were detected using enhanced chemiluminiscence (Luminata, EMD Millipore, USA) and the blots were acquired using the MyECL Imager (Thermo Scientific, USA).
Data are expressed as the means 7S.E.M. Differences between variables with normal distribution were statistically analyzed by ANOVA with Newman-Keuls post-hoc test. Differences were considered as significant at P r0.05. 
